KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

AbCellera Biologics (ABCL) Depreciation & Amortization (IS): 2020-2023

Historic Depreciation & Amortization (IS) for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2023 value amounting to $7.5 million.

  • AbCellera Biologics' Depreciation & Amortization (IS) fell 45.46% to $7.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $24.4 million, marking a year-over-year decrease of 12.39%. This contributed to the annual value of $90.8 million for FY2024, which is 272.41% up from last year.
  • Latest data reveals that AbCellera Biologics reported Depreciation & Amortization (IS) of $7.5 million as of Q4 2023, which was up 31.40% from $5.7 million recorded in Q3 2023.
  • In the past 5 years, AbCellera Biologics' Depreciation & Amortization (IS) ranged from a high of $13.8 million in Q4 2022 and a low of $41,000 during Q3 2020.
  • For the 3-year period, AbCellera Biologics' Depreciation & Amortization (IS) averaged around $5.6 million, with its median value being $5.0 million (2022).
  • In the last 5 years, AbCellera Biologics' Depreciation & Amortization (IS) surged by 8,841.46% in 2021 and then crashed by 45.46% in 2023.
  • AbCellera Biologics' Depreciation & Amortization (IS) (Quarterly) stood at $3.3 million in 2020, then rose by 18.93% to $4.0 million in 2021, then soared by 249.12% to $13.8 million in 2022, then crashed by 45.46% to $7.5 million in 2023.
  • Its Depreciation & Amortization (IS) stands at $7.5 million for Q4 2023, versus $5.7 million for Q3 2023 and $5.6 million for Q2 2023.